Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Caris Life SciencesSTU:49J -0.73%17 PB Ratio is 7.49 as of Jul. 26, 2026, which is 43% below its 10-year median of 13.16. GuruFocus rates STU:49J with a GF Score™ of 17/100. The stock has 2 warning signs investors should review. Among 1,231 Biotechnology companies, Caris Life Sciences ranks worse than 80.26% on this metric.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Caris Life Sciences PB Ratio Related Terms
Caris Life Sciences PB Ratio Historical Data
* Premium members only.
The historical data trend for Caris Life Sciences's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Caris Life Sciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Caris Life Sciences PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Caris Life Sciences's PB Ratio distribution charts can be found below:
* The bar in red indicates where Caris Life Sciences's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Caris Life Sciences (STU:49J) has a PB Ratio of 7.49 as of Jul. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Caris Life Sciences and its competitors. This is 43% below median its historical median of 13.16. Over the past decade, Caris Life Sciences' PB Ratio has ranged from 6.93 to 24.39. According to the industry distribution chart, Caris Life Sciences ranks #988 out of 1231 companies in the Biotechnology industry, placing it in the top 80.3%.
Is Caris Life Sciences' PB Ratio too high?
Caris Life Sciences' current PB Ratio of 7.49 is 43% below median its 10-year median of 13.16. Over the past 10 years, this metric has ranged from a low of 6.93 to a high of 24.39. The Biotechnology industry median PB Ratio is 2.77. Caris Life Sciences' value of 7.49 is 170.4% above this industry median. Based on the distribution chart, Caris Life Sciences ranks #988 out of 1231 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Caris Life Sciences has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Caris Life Sciences' PB Ratio compare to DNTH and MANE?
According to the Biotechnology industry distribution chart, Caris Life Sciences ranks #988 out of 1231 companies for PB Ratio. This places Caris Life Sciences in the lower half of its industry. The industry median PB Ratio is 2.77. Caris Life Sciences' value of 7.49 is 170.4% above this benchmark. Historically, Caris Life Sciences' own PB Ratio has ranged from 6.93 to 24.39 over the past decade. While the company's 10-year median is 13.16 vs. the industry median of 2.77, Caris Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.77, based on 1,231 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Caris Life Sciences's current PB Ratio of 7.49 is 170.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Caris Life Sciences and its competitors. For the Biotechnology industry, the median PB Ratio is 2.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Caris Life Sciences's current PB Ratio is 7.49, which is 43% below median its own 10-year median of 13.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Caris Life Sciences stock overvalued right now?
Caris Life Sciences (STU:49J) has a current PB Ratio of 7.49. The current PB Ratio is 7.49, which is 43% below median its 10-year median of 13.16 and 170.4% above the Biotechnology industry median of 2.77. Caris Life Sciences' overall GF Score™ is 17/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Caris Life Sciences (STU:49J), the current PB Ratio is 7.49 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
17GF Score
Get the complete analysis for STU:49J
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:49J has been successfully added to your 
